Home LiteratureArticle Details
PMID: 1933886 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Activation of the autocrine transforming growth factor alpha pathway in human squamous carcinoma cells.

Cancer research ·Vol. 51 ·No. 23 Pt 1 ·1991-12-01 ·Pages 6254-62

Reiss M, Stash EB, Vellucci VF, Zhou ZL

Abstract

Transforming growth factor alpha is an autocrine mitogen for nonneoplastic keratinocytes, which exerts its function by binding to the receptor for epidermal growth factor. In order to determine whether this autocrine pathway is activated in squamous carcinoma cells, we analyzed the production of transforming growth factor alpha as well as the expression and regulation of epidermal growth factor receptors in a panel of human squamous carcinoma cell lines. Immunoreactive transforming growth factor alpha was detectable in squamous carcinoma cells as well as in quiescent nonneoplastic keratinocytes. However, in the absence of exogenous mitogens, only the squamous carcinoma cells secreted the growth factor into the medium, whereas untransformed keratinocytes did not. Each of the squamous carcinoma cell lines expressed significantly greater numbers of cell surface epidermal growth factor receptors than normal keratinocytes. The epidermal growth factor receptor gene was amplified and overexpressed in three of the squamous carcinoma cell lines (A431, CaSki, SqCC/Y1). Two of the squamous carcinoma cell lines (C4-1 and CE-48) displayed a relative inability to down-regulate epidermal growth factor receptors in response to epidermal growth factor. The mechanism of receptor overexpression in the remaining three cell lines (A253, CaLu-1, FaDu) is unexplained. Thus, human squamous carcinoma cell lines frequently exhibit a combination of the constitutive secretion of transforming growth factor alpha and the overexpression of epidermal growth factor receptors. Treatment of these tumor cells with an antibody directed against the ligand-binding domain of the epidermal growth factor receptor inhibited their growth by approximately 50%. These findings suggest that designing strategies to interrupt the transforming growth factor alpha autocrine pathway might lead to new modalities to treat this class of malignant tumors.

MeSH Terms
Carcinoma, Squamous Cell/metabolism,pathology Cell Division DNA, Neoplasm/biosynthesis Down-Regulation ErbB Receptors/biosynthesis Gene Expression Regulation, Neoplastic Humans Keratinocytes/metabolism RNA, Messenger/biosynthesis RNA, Neoplasm/analysis Transforming Growth Factor alpha/biosynthesis
Chemicals
DNA, Neoplasm RNA, Messenger RNA, Neoplasm Transforming Growth Factor alpha ErbB Receptors
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Reiss M
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06517.
Stash E B
Vellucci V F
Zhou Z L
Article Info
Journal
Cancer research
Abbr.
Cancer Res
ISSN
0008-5472
Published
1991-12-01
Pages
6254-62
Language
English
Region
United States
NLM ID
2984705R
Subset
IM
Grants
NCI NIH HHS · CA-41556 · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com